Gaillard O, Gervais A, Meillet D, Plassart E, Fontaine B, Lyon-Caen O, Delattre J, Schuller E
Laboratory of Clinical Biology, Centre Hospitalier, Blois, France.
J Neurol Sci. 1998 Jun 30;158(2):180-6. doi: 10.1016/s0022-510x(98)00118-x.
Apolipoprotein E (apo E) is postulated to be a major lipid carrier protein in the brain involved in brain development and repair. Multiple sclerosis (MS) is a major demyelinating disease characterized by destruction of myelin and marked alteration of myelin cholesterol and lipid metabolism. We have determined serum and cerebrospinal fluid (CSF) apo E concentrations using an original time-resolved immunofluorometric assay and calculated intrathecal apo E concentration. Apo E concentrations were determined in 13 control subjects and 129 neurological patients: 34 definite MS patients, 25 with Guillain-Barré syndrome (GBS), 32 with amyotrophic lateral sclerosis (ALS) and 38 with other neurological diseases. Seven clinical parameters (sex, age, age at MS onset, duration of the disease, course, clinical status and disability score) were considered in MS patients. Significant (P < 0.01) decrease in CSF apo E was observed in MS, linked to a decrease in intrathecal apo E. The decreased CSF apo E concentration in MS patients occur independent of the apo E genotype. Apo E is considered as a neurotrophic factor in the brain. Any decrease in intrathecal apo E synthesis would thus contribute to progression of neurological diseases, such as MS.
载脂蛋白E（apo E）被认为是大脑中参与脑发育和修复的主要脂质载体蛋白。多发性硬化症（MS）是一种主要的脱髓鞘疾病，其特征是髓鞘破坏以及髓鞘胆固醇和脂质代谢的显著改变。我们使用一种原创的时间分辨免疫荧光分析法测定了血清和脑脊液（CSF）中的apo E浓度，并计算了鞘内apo E浓度。在13名对照受试者和129名神经科患者中测定了apo E浓度：34名确诊的MS患者、25名吉兰 - 巴雷综合征（GBS）患者、32名肌萎缩侧索硬化症（ALS）患者和38名患有其他神经疾病的患者。在MS患者中考虑了七个临床参数（性别、年龄、MS发病年龄、病程、病情、临床状态和残疾评分）。在MS患者中观察到CSF中apo E显著（P < 0.01）降低，这与鞘内apo E降低有关。MS患者CSF中apo E浓度降低与apo E基因型无关。Apo E被认为是大脑中的一种神经营养因子。因此，鞘内apo E合成的任何降低都将导致神经疾病（如MS）的进展。
